Though studies have proven that PD1 blockade can alleviate the intrinsic PD1 inhibition of ILC2 cells to augment antitumor immunity [24], no study has explored the relationship between the levels of ILCs and the balance of ILC1/ILC2 with sPD1 and sPDL1 in the peripheral blood circulation of tumor patients. This evidence concerns the gene SPDL1 and neoplasm.